Grass Pollen Allergic RhinitisNCT01992835
Resolution of Allergic Inflammation
A study testing Grass pollen allergen extract in people with Grass Pollen Allergic Rhinitis, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
After an allergen challenge, the allergic inflammatory response disappears spontaneously. The initiation of the resolution of the inflammatory response is now recognized as a dynamic process, involving active biochemical programs that enable inflamed tissues to return to homeostasis. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Grass Pollen Allergic Rhinitis
- What is being tested?
- Grass pollen allergen extract
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- Nov 2013to Apr 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Allergic rhinitis during the grass pollen season with or without asthma, with at least one of the following symptoms: nasal congestion, itching, rhinorrhea, sneezing
- Grass pollen sensitization determined by a positive skin prick test and / or presence of specific IgEs to a grass pollen allergen extract
Who cannot join
- Smoker
- Specific immunotherapy with grass allergens or other respiratory allergen for inclusion.
- Current exhibition to another clinically relevant respiratory allergen
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Resolution of Allergic Inflammation: Identification and Kinetics of Specific Lipid Mediators During Nasal Allergen Challenge
After an allergen challenge, the allergic inflammatory response disappears spontaneously. The initiation of the resolution of the inflammatory response is now recognized as a dynamic process, involving active biochemical programs that enable inflamed tissues to return to homeostasis. Recent data established key roles of different specific lipid mediators in the endogenous counter-regulation of inflammation and activation of resolution. Only little is known about kinetics of these specialized pro-resolving lipid mediators during acute allergic inflammation. Therefore, the primary propose of our study is to characterize the temporal evolution of cellular inflammation and specific lipid mediators after allergen challenge.
- Conditions
- Grass Pollen Allergic Rhinitis
- Being tested
- Grass pollen allergen extract, placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Grass pollen allergen extractOther
Each subject will be challenged with a grass pollen allergen extract and with placebo.
placeboOther
| Study group | Role | What they receive |
|---|---|---|
| measurement of mediators in biological fluids | Placebo comparator | Not described Receives: Other: placebo |
| Grass pollen allergen extract | Experimental | Not described Receives: Other: Grass pollen allergen extract |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical nasal score and measurement of mediators in biological fluids
Measured: Measurement of mediators in biological fluids during 72 h after nasal allergen challenge
Clinical nasal score and measurement of mediators in biological fluids.
Measured: Measurement and indentification of specific lipid mediators during nasal allergen challenge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2013 (estimated)
- Study startNov 2013
- Primary completionApr 2014
- Study completionApr 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Grass Pollen Allergic RhinitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cindy Barnig, Principal investigator, Pôle de Pathologie Thoracique- Hôpitaux Universitaires Strasbourg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01992835
- Sponsor's protocol ID
- 5507
- Status last verified
- Jan 2026
- First submitted
- 24 Oct 2013
- Last updated
- 20 Jan 2026
- Results posted
- No
Publications
Qi S, Barnig C, Charles AL, Poirot A, Meyer A, Clere-Jehl R, de Blay F, Geny B. Effect of nasal allergen challenge in allergic rhinitis on mitochondrial function of peripheral blood mononuclear cells. Ann Allergy Asthma Immunol. 2017 Mar;118(3):367-369. doi: 10.1016/j.anai.2016.11.026. Epub 2017 Jan 7. No abstract available.
PubMed 28073613
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Resolution of Allergic Inflammation: Identification and Kinetics of Specific Lipid Mediators During Nasal Allergen Challenge
- ClinicalTrials.gov ID
- NCT01992835
- Acronym / sponsor ID
- 5507
- Conditions
- Grass Pollen Allergic Rhinitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- Nov 2013
- Primary completion
- Apr 2014 (actual)
- Study completion
- Apr 2014 (actual)
- First posted
- 25 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
After an allergen challenge, the allergic inflammatory response disappears spontaneously. The initiation of the resolution of the inflammatory response is now recognized as a dynamic process, involving active biochemical programs that enable inflamed tissues to return to homeostasis. Recent data established key roles of different specific lipid mediators in the endogenous counter-regulation of inflammation and activation of resolution. Only little is known about kinetics of these specialized pro-resolving lipid mediators during acute allergic inflammation. Therefore, the primary propose of our study is to characterize the temporal evolution of cellular inflammation and specific lipid mediators after allergen challenge.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| measurement of mediators in biological fluids | Placebo comparator | Other: placebo |
| Grass pollen allergen extract | Experimental | Other: Grass pollen allergen extract |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Allergic rhinitis during the grass pollen season with or without asthma, with at least one of the following symptoms: nasal congestion, itching, rhinorrhea, sneezing
- Grass pollen sensitization determined by a positive skin prick test and / or presence of specific IgEs to a grass pollen allergen extract
Key exclusion criteria (3 listed)
- Smoker
- Specific immunotherapy with grass allergens or other respiratory allergen for inclusion.
- Current exhibition to another clinically relevant respiratory allergen
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Grass pollen allergen extractEach subject will be challenged with a grass pollen allergen extract and with placebo. | Other | Grass pollen allergen extract |
| placebo | Other | measurement of mediators in biological fluids |
Primary outcome
Clinical nasal score and measurement of mediators in biological fluids
Time frame: Measurement of mediators in biological fluids during 72 h after nasal allergen challenge
Clinical nasal score and measurement of mediators in biological fluids.
Time frame: Measurement and indentification of specific lipid mediators during nasal allergen challenge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Results publication: PubMed 28073613Qi S, Barnig C, Charles AL, Poirot A, Meyer A, Clere-Jehl R, de Blay F, Geny B. Effect of nasal allergen challenge in allergic rhinitis on mitochondrial function of peripheral blood mononuclear cells. Ann Allergy Asthma Immunol. 2017 Mar;118(3):367-369. doi: 10.1016/j.anai.2016.11.026. Epub 2017 Jan 7. No abstract available.
Related trials for Grass Pollen Allergic Rhinitis
RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
Recruiting
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Allergic Asthma, Thunderstorm Asthma
Recruiting
Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project
Allergic Rhinitis
Active, not recruitingObservational study
Tyrosine Allergoid Paediatric and Adult Study
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
RecruitingPhase 3
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Rhinitis, Allergic, Rhinoconjunctivitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cindy Barnig principal investigator
Pôle de Pathologie Thoracique- Hôpitaux Universitaires Strasbourg
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Grass pollen allergen extract in people with Grass Pollen Allergic Rhinitis, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical nasal score and measurement of mediators in biological fluids (time frame: Measurement of mediators in biological fluids during 72 h after nasal allergen challenge). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01992835, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.